High-dose statins and the IDEAL study: To the editor [5]

JAMA

Volumn 295, Issue 21, 2006, Pages 2477-2478

  Mann, Samuel J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MEGADOSE; HEART INFARCTION; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; BLOOD; NOTE;

CHOLESTEROL, LDL; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PYRROLES; SIMVASTATIN;

EID: 33744950401     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.21.2477-b     Document Type: Letter

References (1)

1. Pedersen TR, Faergeman O, Kastelein JJP, et al; for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.